Trial Profile
A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Pharmacogenomic; Therapeutic Use
- 20 Apr 2020 Results published in the Clinical Cancer Research
- 31 Oct 2018 Status changed to discontinued, according to linicalTrials.gov record.
- 16 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.